Donna M. Weber

Hematology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 108 publications

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Journal: Blood

Published: December 02, 2025

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: October 31, 2025

Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.

Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 28, 2025

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis.

Journal: American journal of hematology

Published: September 03, 2025

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy.

Journal: Blood cancer journal

Published: July 07, 2025

Phase I study of pomalidomide in relapsed or refractory Waldenström macroglobulinaemia.

Phase I study of pomalidomide in relapsed or refractory Waldenström macroglobulinaemia.

Journal: British journal of haematology

Published: April 09, 2025

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.

Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel.

Journal: Blood advances

Published: August 12, 2024

Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.

Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.

Journal: Cell reports. Medicine

Published: June 10, 2024

Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.

Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.

Journal: British journal of haematology

Published: November 10, 2023

Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.

Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience.

Journal: Blood cancer journal

Published: October 02, 2023

Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.

Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.

Journal: Transplantation and cellular therapy

Published: July 24, 2023

Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.

Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.

Journal: Cancer

Published: June 29, 2023

Showing 1-12 of 108

Last Updated: 09/26/2026